Assertio Holdings, Inc. (ASRT) - What You Need to Know About the Buyout

If you follow Assertio Holdings (ASRT), you have likely seen the big news. The company is being acquired. Here is the plain-English breakdown of what this means for you.

1. What happened?

Assertio signed a deal to be bought by Zydus Worldwide DMCC, a branch of Zydus Lifesciences Limited. This is an all-cash deal. Zydus will pay $23.50 for every share you own. Once the deal closes, Assertio will become a private company, and its shares will no longer trade on the stock market.

2. Why did it happen?

Assertio previously had a deal with Garda Therapeutics. However, Zydus offered more money. Assertio’s board decided the Zydus offer was better for shareholders. To switch to the Zydus deal, Assertio ended its agreement with Garda and paid a $5.8 million breakup fee. The board believes this move provides the best value for investors by offering a guaranteed cash exit.

3. Why does this matter?

This changes your investment outlook. When a company is bought for a set cash price, the stock price usually hovers near that $23.50 offer until the deal closes.

• The "No Shop" Clause: Assertio agreed not to look for or accept other offers. This locks in the current deal as the final path forward.
• The "Rolvedon" Factor: Assertio’s business model relies heavily on Rolvedon, a drug for chemotherapy patients. The board chose this buyout to provide a guaranteed cash exit, effectively allowing investors to avoid the long-term risks associated with relying on a single product.

4. Who is affected?

• Investors: If you own the stock, you will receive $23.50 in cash per share once the deal closes.
• Employees: As the company becomes a private subsidiary, management and operations may change. The company noted that this transition could distract staff from their daily work, which is a standard risk mentioned in these types of filings.

5. What happens next?

The deal needs approval from shareholders and regulators. Zydus must start a "tender offer" within five business days. This is the formal process where they invite you to sell your shares to them for $23.50.

• Watch for the paperwork: Look for the "Schedule TO" from Zydus and the "Schedule 14D-9" from Assertio. These explain exactly how to tender your shares. You can find them at sec.gov or the Assertio Investor Relations website.
• Timeline: The deal is expected to close by July 12, 2026, assuming all regulatory conditions are met.

6. What should you know before you act?

• Don't expect massive growth: Since the price is fixed at $23.50, the stock will likely stay near that price. It may trade slightly lower to account for the time it takes to close and the small risk that the deal could fall through.
• The "Spread": The difference between the current market price and the $23.50 offer is known as the "arbitrage spread." If the stock is trading at $23.00, for example, that $0.50 difference represents the market's assessment of the risk that the deal might not close.
• Stay informed: Read the official documents once they arrive. They contain the legal details and any specific risks that could affect your final payout.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and is not professional investment advice. Always do your own research before making a trade.